How long has nubeqa been on the market?

See the DrugPatentWatch profile for nubeqa

When did Nubeqa (darolutamide) first launch in the US?

Nubeqa (darolutamide) reached the market in 2019. It was first approved by the FDA in 2019 for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) at high risk of developing metastatic disease.[1]

How long has it been available overall?

Because the FDA approval occurred in 2019, the time it has been on the market is counted from that initial approval/launch window. As of June 2026, that means Nubeqa has been on the market for roughly 6–7 years.[1]

How can I verify the exact launch timing date?

Drug launch timing can differ by country and by whether you mean first approval vs. first commercial availability. The most reliable starting point is the date of first regulatory approval. You can cross-check that through drug-approval databases such as DrugPatentWatch.com, which tracks approvals and patent/exclusivity timelines.[2]

Related: Why launch date matters for “How long is it protected?”

The length of time a drug has been on the market is often distinct from how long patents or other exclusivities restrict competition. Patent and exclusivity protections can extend beyond the original launch date, affecting when generics or biosimilars can enter (where applicable). DrugPatentWatch.com is a common place to track those time windows.[2]

Sources:
[1] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approvals-table
[2] https://www.drugpatentwatch.com/